Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Corcept Therapeutics
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05772169CT.gov Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Type 2 Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mifepristone (this asset) | Corcept Therapeutics | Approved | B · 61 |
| Liraglutide | RenJi Hospital | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
| Dapagliflozin | Bhavya Bhavya, MD | P4 | BBB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Cotadutide | AstraZeneca | P2 | BBB |
| Metformin | Myopharm Limited | P4 | BBB |
| Saxagliptin | Nick Giannoukakis, PhD | P4 | BBB |
| Pioglitazone | Seoul National University Bundang Hospital | P4 | BBB |
+41 more in the Type 2 Diabetes Mellitus cohort
Other indications for Mifepristone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psychotic Disorder | — | P3 | BB · 64 |
| Major Depressive Disorder | — | P3 | B · 63 |
| Cushing Syndrome | — | P4 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mifepristone in Type 2 Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/mifepristone-type-2-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →